Allen-Vanguard Corporation Announces Filing of Preliminary short-form Prospectus for Special Warrants issue


    OTTAWA, Sept. 14 /CNW Telbec/ - Allen-Vanguard Corporation
("Allen-Vanguard" or the "Company") (TSX:VRS) is pleased to announce that,
further to its news release dated August 15, 2007, it has filed its
preliminary short form prospectus with Canadian securities regulatory
authorities qualifying the distribution of 14,650,000 common shares (the
"Common Shares") of the Company issuable (without any further action by the
holder thereof and for no additional consideration) upon the deemed exercise
of 14,650,000 previously issued special warrants of the Company (the "Special
Warrants") in the provinces of Ontario and Quebec.
    On August 15, 2007, the Company sold and issued 14,650,000 subscription
receipts (the "Subscription Receipts"), by way of private placement, pursuant
to prospectus exemptions under applicable securities legislation. The
Subscription Receipts were sold to subscribers at a price of $6.85 per
Subscription Receipt for aggregate gross proceeds of $100,352,500. Each of the
Subscription Receipts will be automatically exercised (without any further
action by the holder thereof and for no additional consideration) for one
Special Warrant of the Company concurrently with the satisfaction of certain
conditions, including the completion of the acquisition of Med-Eng Systems
Inc. (Med-Eng).
    Each Special Warrant entitles the holder thereof to receive, upon the
deemed exercise of the Special Warrant (without any further action by the
holder thereof and for no additional consideration), subject to adjustment in
certain events, one Common Share at 5:00 p.m. (Toronto time) on the earliest
of: (i) the third business day after the date a receipt is issued by the
securities regulatory authorities in a jurisdiction of Canada for a final
short form prospectus qualifying the Common Shares to be issued upon the
deemed exercise of the Special Warrants; and (ii) December 16, 2007.

    The acquisition of Med-Eng was funded through a combination of

    - $100 million in this subscription receipts private placement for
      14.65 million common shares of the Company at a price of $6.85 per
    - $350 million in five-year term debt financing ("Senior Debt Facility")
      at LIBOR plus 7%;
    - $150 million in subordinated debt from a consortium of lenders
      ("Subordinated Debt"). The Subordinated Debt funds will be advanced on
      October 1st, 2007, and will be repayable on December 31st, 2007,
      subject to potential extension. The vendor also received Subordinated
      Debt in the amount of the excess working capital.
    - $15 million in a revolving credit facility ("Revolver Facility").

    In addition, in connection with the transaction to purchase Med-Eng.,
Allen-Vanguard filed a preliminary short form prospectus (the "Prospectus") on
August 31, 2007 pursuant to which it intends to issue approximately
$200 million in common shares, to be priced in the context of the market, with
a potential 15% over allotment. The Company intends to use these funds to
retire the Subordinated Debt and repay a portion of the Senior Debt Facility
(the Prospectus is available on SEDAR at This will result in a
permanent financing structure of the acquisition of approximately $300 million
in new long term debt and approximately $300 million in new equity.

    This news release does not constitute an offer to sell or a solicitation
of an offer to buy any of the securities in the United States. The securities
have not and will not be registered under the United States Securities Act of
1933, as amended, or any state securities laws and may not be offered or sold
within the United States or to U.S. Persons (as such term is defined in
Regulation S of the United States Securities Act of 1933, as amended) unless
an exemption from such registration is available. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy nor shall
there be any sale of the securities in any State in which such offer,
solicitation or sale would be unlawful.

    About Allen-Vanguard

    Allen-Vanguard Corporation and its subsidiaries worldwide operate under
the brand "Allen-Vanguard". Allen-Vanguard develops and markets technologies,
tools and training for defeating and minimizing the effects of hazardous
devices and materials, whether Chemical, Biological, Radiological, Nuclear or
Explosive ("CBRNE"). Allen-Vanguard's equipment is in service with leading
security and military forces in more than 120 countries. Products include
Electronic Counter-Measures ("ECM") equipment for jamming remote detonation of
terrorist devices, specialty security equipment for Explosive Ordnance
Disposal ("EOD"), remote intervention robots for hazardous applications,
vehicle barrier systems, and personal protective wear for use in dealing with
bio-chemical agents. Allen-Vanguard is the sole, worldwide licensee and/or
developer of patented technologies such as the Universal Containment System
and CASCAD Foam for blast mitigation and decontamination of bio-chemical
warfare agents. Head office operations are located in Ottawa, Ontario, Canada,
with manufacturing operations in Stoney Creek, Ontario; Tewkesbury, U.K.; and
Cork, Ireland, and sales offices in Canada, the U.S., the U.K. and Asia.
Allen-Vanguard's shares are listed on The Toronto Stock Exchange (TSX: VRS).

    This press release contains forward-looking statements, which reflect
Allen-Vanguard's current expectations regarding future events, its strategy,
expected performance and condition. Forward-looking statements include
statements that are predictive in nature, that depend upon or refer to future
events or conditions, or that include words such as "expects," "anticipates,"
"plans," "believes," "estimates" or negative versions thereof and similar
expressions. In addition, any statement that may be made concerning future
performance, strategies or prospects, and possible future acquisitions or
dispositions, is also a forward-looking statement. Forward-looking statements
are based on current expectations and projections about future events and are
inherently subject to, among other things, risks, uncertainties and
assumptions about the Company and economic factors. Forward-looking statements
are not promises or guarantees of future performance, and actual events and
results could differ materially from those expressed or implied in any
forward-looking statements made about the Company. Any number of important
factors could contribute to these digressions, including, but not limited to,
general economic, political and market factors in North America and
internationally, interest and foreign exchange rates, global equity and
capital markets, business competition, technological change, changes in
government regulations, unexpected judicial or regulatory proceedings, and
catastrophic events. We stress that the above-mentioned list of important
factors is not exhaustive. We encourage you to consider these and other
factors carefully before making any investment decision and we urge you to
avoid placing undue reliance on forward-looking statements. Further, you
should be aware that the Company disclaims any obligation to publicly update
or revise any such forward-looking statements whether as a result of new
information, future events or otherwise, prior to the release of the next
Management Discussion and Analysis to be released by the Company or except as
required by law.

    To find out more about Allen-Vanguard Corporation (TSX: VRS), visit our
website at
    %SEDAR: 00018026E

For further information:

For further information: Elisabeth Preston, (613) 614-4884

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890